avelumab-话题@MedSci

#avelumab#

29篇内容 | 2274人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1348502, encodeId=737b1348502c6, content=<a href='/topic/show?id=3c1630303e' target=_blank style='color:#2F92EE;'>#avelumab#</a>, objectTitle=Blood：Avelumab治疗复发性/难治性结外NK/T细胞淋巴瘤, objectType=article, longId=199475, objectId=ce771994e50b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ce771994e50b, replyNumber=0, likeNumber=63, createdTime=2020-08-16, rootId=0, userName=fangcong, userId=b79433, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ce771994e50b, moduleTitle=Blood：Avelumab治疗复发性/难治性结外NK/T细胞淋巴瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ce771994e50b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1348501, encodeId=4ed213485010d, content=<a href='/topic/show?id=3c1630303e' target=_blank style='color:#2F92EE;'>#avelumab#</a>, objectTitle=治疗性疫苗TG4001联合Avelumab治疗晚期HPV阳性癌症：临床试验取得积极结果, objectType=article, longId=197970, objectId=196819e970eb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=196819e970eb, replyNumber=0, likeNumber=81, createdTime=2020-07-25, rootId=0, userName=fangcong, userId=b79433, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=196819e970eb, moduleTitle=治疗性疫苗TG4001联合Avelumab治疗晚期HPV阳性癌症：临床试验取得积极结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=196819e970eb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1348500, encodeId=d2fb134850020, content=<a href='/topic/show?id=3c1630303e' target=_blank style='color:#2F92EE;'>#avelumab#</a>, objectTitle=ASCO 2020丨晚期尿路上皮癌又有新进展，Avelumab维持治疗联合BSC可使总生存期延长7.1个月！, objectType=article, longId=195300, objectId=951f1953003d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=951f1953003d, replyNumber=0, likeNumber=58, createdTime=2020-06-06, rootId=0, userName=fangcong, userId=b79433, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=951f1953003d, moduleTitle=ASCO 2020丨晚期尿路上皮癌又有新进展，Avelumab维持治疗联合BSC可使总生存期延长7.1个月！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=951f1953003d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1348499, encodeId=285613484996f, content=<a href='/topic/show?id=3c1630303e' target=_blank style='color:#2F92EE;'>#avelumab#</a>, objectTitle=如何治疗耐药性罕见妇科癌症？免疫疗法Avelumab表现出众, objectType=article, longId=194970, objectId=e87b1949e07f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e87b1949e07f, replyNumber=0, likeNumber=68, createdTime=2020-05-31, rootId=0, userName=fangcong, userId=b79433, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e87b1949e07f, moduleTitle=如何治疗耐药性罕见妇科癌症？免疫疗法Avelumab表现出众, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e87b1949e07f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1348498, encodeId=497513484989d, content=<a href='/topic/show?id=3c1630303e' target=_blank style='color:#2F92EE;'>#avelumab#</a>, objectTitle=NEJM：Avelumab加阿西替尼与舒尼替尼治疗晚期肾细胞癌的疗效比较, objectType=article, longId=162682, objectId=970d162682a2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=970d162682a2, replyNumber=0, likeNumber=104, createdTime=2019-03-22, rootId=0, userName=fangcong, userId=b79433, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=970d162682a2, moduleTitle=NEJM：Avelumab加阿西替尼与舒尼替尼治疗晚期肾细胞癌的疗效比较, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=970d162682a2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1348497, encodeId=be71134849e21, content=<a href='/topic/show?id=3c1630303e' target=_blank style='color:#2F92EE;'>#avelumab#</a>, objectTitle=NEJM: BAVENCIO（avelumab）联合INLYTA（阿西替尼）在晚期肾细胞癌中的关键性III期数据, objectType=article, longId=160425, objectId=2800160425be, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2800160425be, replyNumber=0, likeNumber=57, createdTime=2019-02-20, rootId=0, userName=fangcong, userId=b79433, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2800160425be, moduleTitle=NEJM: BAVENCIO（avelumab）联合INLYTA（阿西替尼）在晚期肾细胞癌中的关键性III期数据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2800160425be)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1348496, encodeId=62e813484964d, content=<a href='/topic/show?id=3c1630303e' target=_blank style='color:#2F92EE;'>#avelumab#</a>, objectTitle=辉瑞/默克公司的avelumab与Inlyta联合治疗取得突破性进展, objectType=article, longId=124448, objectId=629b1244488f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=629b1244488f, replyNumber=0, likeNumber=55, createdTime=2017-12-25, rootId=0, userName=fangcong, userId=b79433, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=629b1244488f, moduleTitle=辉瑞/默克公司的avelumab与Inlyta联合治疗取得突破性进展, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=629b1244488f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1348495, encodeId=2dc8134849563, content=<a href='/topic/show?id=3c1630303e' target=_blank style='color:#2F92EE;'>#avelumab#</a>, objectTitle=Lancet oncol：Avelumab，抗PD-L1单克隆抗体，为对铂类不敏感的转移性尿路上皮癌患者带来新的希望。, objectType=article, longId=122363, objectId=cb2d122363b2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cb2d122363b2, replyNumber=0, likeNumber=68, createdTime=2017-12-07, rootId=0, userName=fangcong, userId=b79433, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cb2d122363b2, moduleTitle=Lancet oncol：Avelumab，抗PD-L1单克隆抗体，为对铂类不敏感的转移性尿路上皮癌患者带来新的希望。, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cb2d122363b2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1348494, encodeId=c9061348494e6, content=<a href='/topic/show?id=3c1630303e' target=_blank style='color:#2F92EE;'>#avelumab#</a>, objectTitle=LANCET ONCOL：Avelumab用于治疗转移或复发非小细胞肺癌, objectType=article, longId=94255, objectId=f81b9425536, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f81b9425536, replyNumber=0, likeNumber=51, createdTime=2017-04-03, rootId=0, userName=fangcong, userId=b79433, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f81b9425536, moduleTitle=LANCET ONCOL：Avelumab用于治疗转移或复发非小细胞肺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f81b9425536)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1348493, encodeId=c30613484933c, content=<a href='/topic/show?id=3c1630303e' target=_blank style='color:#2F92EE;'>#avelumab#</a>, objectTitle=The Lancet Oncology：Avelumab用于转移性或局部晚期实体瘤, objectType=article, longId=94245, objectId=80ff942459a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=80ff942459a, replyNumber=0, likeNumber=49, createdTime=2017-04-02, rootId=0, userName=fangcong, userId=b79433, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=80ff942459a, moduleTitle=The Lancet Oncology：Avelumab用于转移性或局部晚期实体瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=80ff942459a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1348492, encodeId=53271348492aa, content=<a href='/topic/show?id=3c1630303e' target=_blank style='color:#2F92EE;'>#avelumab#</a>, objectTitle=Lancet Oncol：Avelumab或是Merkel细胞癌治疗新选择, objectType=article, longId=77001, objectId=2133e700156, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2133e700156, replyNumber=0, likeNumber=69, createdTime=2016-09-10, rootId=0, userName=fangcong, userId=b79433, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2133e700156, moduleTitle=Lancet Oncol：Avelumab或是Merkel细胞癌治疗新选择, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2133e700156)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1348491, encodeId=011f134849186, content=<a href='/topic/show?id=3c1630303e' target=_blank style='color:#2F92EE;'>#avelumab#</a>, objectTitle=PD-L1免疫治疗药物avelumab牵手表观药物entinostat，联合治疗卵巢癌研究启动, objectType=article, longId=61803, objectId=98bd618032f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=98bd618032f, replyNumber=0, likeNumber=63, createdTime=2016-01-09, rootId=0, userName=fangcong, userId=b79433, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=98bd618032f, moduleTitle=PD-L1免疫治疗药物avelumab牵手表观药物entinostat，联合治疗卵巢癌研究启动, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=98bd618032f)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

avelumab

2020-05-29

fangcong (审核中...)

前往app查看评论内容

#avelumab#

Blood：Avelumab治疗复发性/难治性结外NK/T细胞淋巴瘤

2020-08-16

fangcong (审核中...)

前往app查看评论内容

#avelumab#

治疗性疫苗TG4001联合Avelumab治疗晚期HPV阳性癌症：临床试验取得积极结果

2020-07-25

fangcong (审核中...)

前往app查看评论内容

#avelumab#

ASCO 2020丨晚期尿路上皮癌又有新进展，Avelumab维持治疗联合BSC可使总生存期延长7.1个月！

2020-06-06

fangcong (审核中...)

前往app查看评论内容

#avelumab#

如何治疗耐药性罕见妇科癌症？免疫疗法Avelumab表现出众

2020-05-31

fangcong (审核中...)

前往app查看评论内容

#avelumab#

NEJM：Avelumab加阿西替尼与舒尼替尼治疗晚期肾细胞癌的疗效比较

2019-03-22

fangcong (审核中...)

前往app查看评论内容

#avelumab#

NEJM: BAVENCIO（avelumab）联合INLYTA（阿西替尼）在晚期肾细胞癌中的关键性III期数据

2019-02-20

fangcong (审核中...)

前往app查看评论内容

#avelumab#

辉瑞/默克公司的avelumab与Inlyta联合治疗取得突破性进展

2017-12-25

fangcong (审核中...)

前往app查看评论内容

#avelumab#

Lancet oncol：Avelumab，抗PD-L1单克隆抗体，为对铂类不敏感的转移性尿路上皮癌患者带来新的希望。

2017-12-07

fangcong (审核中...)

前往app查看评论内容

#avelumab#

LANCET ONCOL：Avelumab用于治疗转移或复发非小细胞肺癌

2017-04-03

fangcong (审核中...)

前往app查看评论内容

#avelumab#

The Lancet Oncology：Avelumab用于转移性或局部晚期实体瘤

2017-04-02

fangcong (审核中...)

前往app查看评论内容

#avelumab#

Lancet Oncol：Avelumab或是Merkel细胞癌治疗新选择

2016-09-10

fangcong (审核中...)

前往app查看评论内容

#avelumab#

PD-L1免疫治疗药物avelumab牵手表观药物entinostat，联合治疗卵巢癌研究启动

2016-01-09

科室
- - 订阅+
  - 更多科室
工具
服务